cellumenIlluminating Cellular Systems Biology
Overview Leadership Team Board of Directors Scientific Advisory Board Partnerships Careers Contact Us
Overview Cellular Systems Biology CellCiphr™ Cellular Models of Disease CellCiphr™ Cytotoxicity Profiling CellCiphr™ Patient Profiling Key Definitions
Overview Press Release Calendar of Events Publications

Company

Leadership Team

Key Leaders at Cellumen

The Cellumen management team represents an impressive collective of business acumen and scientific expertise.



D. Lansing Taylor, Ph.D., President and CEO

Dr. Taylor is the President and CEO of Cellumen, Inc. Dr. Taylor was the Founder, Chairman, and CEO of Cellomics, Inc. He was a co-founder, member of the Board, and a scientific advisor to Biological Detection Systems, Inc. until it was sold to Amersham Biosciences in 1996. Dr. Taylor was a Professor of Biological Sciences, Vice Dean of Molecular Sciences, and Director of the National Science Foundation, Science and Technology Center (STC) at Carnegie Mellon between 1982 and 1996. He was a pioneer in the development of instrumentation and fluorescence-based reagents to measure the functions of living cells. He continues as an Adjunct Professor at Carnegie Mellon. Dr. Taylor began his academic and research career at Harvard University.

Dr. Taylor is on the Board of Directors of the Pittsburgh Life Sciences Greenhouse, NetHealth Systems, Inc., PA BIO, and Celsense, Inc. He received the 1996 Computer World, Smithsonian Award in Science for the work performed by the STC on functional imaging of live cells. He was named entrepreneur of the year in Western Pennsylvania by Ernst and Young in 2001 and entrepreneur of the year in 2002 by the Carnegie Science Center and the Pittsburgh Technology Council. Dr. Taylor holds more than 12 patents.

Gregory Finerty, CPA, Vice-President, Finance, CFO

Mr. Finerty joined Cellumen Inc. in 2005 as Vice President of Finance and CFO. Prior to joining the Company, he spent 30 years at PriceWaterhouseCoopers, the last 20 years as an audit partner before retiring in 2000. He received his Bachelor of Science degree in Accounting from Franciscan University in Ohio and is a Certified Public Accountant.

Kenneth A. Giuliano, Ph. D., Principal Scientist

Dr. Giuliano currently serves as a Principal Scientist at Cellumen, Inc. where he is involved in the development and integration of new cell-based reagents and multiplexed HCS assays. Dr. Giuliano was formerly a Principal Scientist at Cellomics. He was also an Assistant Professor in the Departments of Neurological Surgery and Cell Biology and Physiology at the University of Pittsburgh Cancer Institute. He has authored more than 40 papers on the creation and use of advanced, fluorescence-based reagents and High Content Screening. Dr. Giuliano has authored or co-authored 15 patents. Dr. Giuliano received his Ph.D. in Biochemistry from Colorado State University.

Albert Gough, Ph.D., Vice-President, Discovery Technology

Dr. Gough is the Vice President of Discovery Technology at Cellumen. He joined the Company in 2005 and oversees the integration of screening technologies, Informatics, Information Technology, Operations and Intellectual Property. Dr. Gough has a strong knowledge-base in cell biology, biophysics, digital imaging, optical engineering and product development. He was the Vice President of Research and Development and the Vice President of Operations at Cellomics Inc. before joining Cellumen. Dr. Gough earned his doctorate in Biophysics from Carnegie Mellon University where he subsequently served as the Director of Imaging Technology at the Center of Light Microscope Imaging and Biotechnology at Carnegie Mellon University. He has authored or co-authored 6 patents in the areas of data analysis, cell-based screening and fluorescence-based reactions.

Patricia A. "Kate" Johnston, Ph.D., Vice-President, Discovery Programs

Dr. Johnston joined Cellumen in 2005. Prior to joining Cellumen, she was the Director of Lead Generation Biology at Eli Lilly and Co. from 2001 to 2005, responsible for Assay Development and High Throughput Screening at Lilly's Center of Excellence in Research Triangle Park, NC. From 1993 – 2001 Dr. Johnston served as Head of the Assay Development function at Sphinx Pharmaceuticals which was acquired by Lilly in 1994. Dr. Johnston received her doctoral training in Cell Biology from Duke University Medical Center and pursued post-doctoral training at the Howard Hughes Medical Institute in Dallas.

Dr. Johnston serves on the Lead Development Team of the NIMH-funded Spinal Muscular Atrophy Project, the HTS Steering Committee of the National Toxicology Project, the NIH Special Emphasis Panel for HTS in the MLSCN, and is an ad hoc reviewer for several NIMH study sections and journals.